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Abstract
Background: Although patients have more problems using metered dose inhalers, clinical comparisons suggest
they provide similar control to dry powder inhalers. Using real-life situations this study was designed to evaluate
asthma control in outpatients with moderate to severe persistent asthma and to compare efficacy of fixed
combinations of inhaled corticosteroids (ICS) and long acting beta-agonists (LABA).
Methods: This real-life study had a cross-sectional design. Patients using fixed combinations of ICS and LABA had
their asthma control and spirometry assessed during regular visits.
Results: 111 patients were analyzed: 53 (47.7%) received maintenance therapy of extrafine beclomethasone-
formoterol (BDP/F) pressurized metered dose inhaler (pMDI), 25 (22.5%) fluticasone-salmeterol (FP/S) dry powder
inhaler (DPI), and 33 (29.7%) budesonide-formoterol (BUD/F) DPI. Severity of asthma at time of diagnosis, assessed
by the treating physician, was comparable among groups. Asthma control was achieved by 45.9% of patients;
38.7% were partially controlled and 15.3% were uncontrolled. In the extrafine BDF/F group, asthma control total
score, daytime symptom score and rescue medication use score were significantly better than those using fixed
DPI combinations (5.8 ± 6.2 vs. 8.5 ± 6.8; 1.4 ± 1.8 vs. 2.3 ± 2.1; 1.8 ± 2.2 vs. 2.6 ± 2.2; p = 0.0160; p = 0.012 and p
= 0.025, respectively) and the mean daily ICS dose were significantly lower.
Conclusions: pMDI extrafine BDP/F combination demonstrated better asthma control compared to DPIs
formulated with larger particles. This could be due to the improved lung deposition of the dose or less reliance on
the optimal inhalation technique or both.
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Background
While asthma represents a global public health issue
d u et oh i g hp r e v a l e n c er a t e sin the general population
(ranging from 1% to 18% of the population in different
Countries), several studies now indicate that the impact
on public health is even more severe due to the diffi-
culty in achieving full disease control with available
therapies [1,2]. Indeed, achieving and maintaining
asthma control is the major goal of asthma care. Based
on the Global Initiative for Asthma (GINA) 2009 guide-
lines, asthma control can be assessed by taking into con-
sideration different characteristics including daytime
symptoms, nocturnal awakenings, need of rescue medi-
cation, limitation of physical activity, and lung function
[2]. Randomized clinical trials (RCTs) have shown that
* Correspondence: tamasi@pulm.sote.hu
† Contributed equally
1Department of Pulmonology, Semmelweis Medical University, Budapest,
Hungary
Full list of author information is available at the end of the article
Müller et al. BMC Pulmonary Medicine 2011, 11:40
http://www.biomedcentral.com/1471-2466/11/40
© 2011 Müller et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.current therapeutic asthma treatments are efficient in
granting good asthma control [3]. However, efficacy
results reported in RCTs are often inconsistent with
data observed in real-life settings where asthma control
still remains an unmet need for the great majority of
patients [1,4]. Despite the variety of treatment options
available and the periodical update of GINA guidelines
since 1995, the evidence indicates suboptimal asthma
control, even if improvements are evident when com-
paring more recent data [1] with previous ones [5], in a
great number of patients.
However, RCTs are performed under highly controlled
settings and in selected populations of patients. Under
these controlled conditions, good inhalation technique is
usually checked and granted and the importance of
compliance is emphasized. Such a level of adherence is
not to be expected in real-life settings. In an effort to
find a strategy leading to improved asthma care, the
International Primary Care Respiratory Group (IPCRG)
examined the main factors contributing to poor control
of the disease [6]. Among the several identified reasons,
wrong diagnosis, smoking, co-morbidities, individual
variation in response to treatment, poor adherence, and
poor inhalation technique have been described.
Inhalers for fixed combinations of ICS and LABA
include pMDIs and DPIs. It is known that choice of the
correct inhaler device is crucial since sub-optimal inha-
lation techniques can result in reduced drug delivery
and efficacy and it should be adjusted to different
patients [7,8]. A meta-analysis of RCTs comparing the
same drug delivered by different devices concluded that
efficacy outcomes do not differ significantly and that
pMDIs and DPIs are equally efficacious in clinical set-
tings [9,10], although studies have shown that there are
fewer inhalation errors with some DPIs [11-13].
A new fixed combination of BDP/F has been recently
developed. The innovative formulation of BDP/F pMDI
is characterized by extrafine particle size [14] which
results in improved lung deposition and allows for uni-
form treatment of inflammation and bronchoconstric-
tion throughout the entire bronchial tree [15]. This can
translate into beneficial asthma outcomes as demon-
strated by a significant increase in asthma control vs. a
combination of the same drugs (BDP plus F) given as
larger (not extrafine) particles [16]. It has been reported
that the extrafine formulation of BDP/F allows for a
longer duration of the aerosol plume and a reduced
need for hand-to-lung coordination, thus facilitating
patient inhaler technique [17]. Furthermore, it has been
suggested that pMDI inhalation technique for formula-
tions that produce extrafine particles is less critical than
with other MDIs [8], because lung deposition is less
affected by inhalation flow [18] and coordination [19].
Moreover, the fast onset of bronchodilation may
improve patient adherence [20] and contribute to
efficacy.
The aim of this observational study was to evaluate
the level of asthma control in a group of patients with
moderate or severe persistent asthma (at the time of
diagnosis) and to compare, in a real-life setting, efficacy
outcomes achieved with extrafine BDP/F delivered via
pMDI vs. ICS-LABA combinations (FP/S and BUD/F)
delivered via DPIs.
Methods
Study design and patients
This real-life study had a cross-sectional design and
involved a group of asthmatic outpatients from the
Department of Pulmonology, Semmelweis University
Budapest, Hungary. Patients were consecutively
recruited during their regular visits to the outpatient
department from May 2008 until August 2008.
Male and female asthma patients aged above 18
years were eligible for inclusion in the study if: 1) they
had a diagnosis of moderate or severe persistent
asthma confirmed by chest physician; 2) diagnosis
occurred at least 6 months before the beginning of the
study; 3) they were treated with fixed combination of
ICS and LABA as maintenance therapy; 4) they did
not change their medication within the last 4 weeks
prior to start of study; 5) they had no asthmatic
exacerbation within the last 6 weeks prior to start of
study. Patients were excluded if they had any other
chronic disease (except chronic rhinitis), extreme obe-
sity, or if any acute disease occurred within the last 6
weeks prior to start of study. Patients were enrolled
regardless of their smoking history or habit. Asthma
severity was evaluated at the time of diagnosis and
assessed by the treating physician.
The study was approved by the institutional Ethics
Committee of the Department of Pulmonology, Sem-
melweis University. No consent was obtained from the
participants as it was a non-interventional retrospective
data analysis of the real-life data collected on the usual
visits of patients. No intervention was done only for the
sake of the study.
Assessment of asthma control
Asthma control was assessed by patients using a
questionnaire (Table 1) developed on the basis of the
GINA Guidelines. A score ≤ 4 indicated well con-
trolled asthma, a score >14 reflected uncontrolled
asthma, and intermediate scores were indicative of
partially controlled asthma. Patients were asked to
fill in the questionnaire during their regular clinic
visits.
To determine if other factors may influence the level
of asthma control, the following information was
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ing status, history of allergy, asthma maintenance and
reliever therapy.
Spirometric measurements were performed and data
on forced expiratory volume at 1 s (FEV1), peak expira-
tory flow (PEF), forced expiratory flow between 25 and
75% (FEF 25-75%), maximum expiratory flow (MEF)
25%, and MEF 75% were collected. Lung function was
analyzed using an electronic spirometer (PDD-301/s,
Piston, Budapest, Hungary) according to the American
Thoracic Society (ATS) guidelines [21].
Statistical Analysis
Data were analyzed with the MEDCALC statistical pro-
gram package. Normal distribution was checked and
tested formally by the Kolmogorov-Smirnov test. Differ-
ences between groups were tested by parametric or non-
parametric tests as appropriate. The Student t test was
used to test differences in case of normal distribution
between the groups. Kruskal-Wallis and Mann-Whitney
U tests were used for statistical comparison of the
groups in case of non-normal distribution. Chi-square
test was used where indicated. The level of significance
was set at 0.05.
Results
Clinical data of the patients
The study included 111 patients (81 women and 30 men).
For the purpose of the study, patients were divided in two
groups depending on the inhaler device they were using
(pMDI or DPI). No significant difference in patient char-
acteristics between these two groups was found (Table 2).
The severity of patients was similar in both groups. Lung
function values measured at the time of diagnosis, on the
basis of which patients were characterized as moderate or
severe asthmatics, were not available. Lung function values
that are indicated in Table 2 were measured during patient
visits (using regular asthma maintenance therapy). No sig-
nificant difference was detected between the two treat-
ment groups in terms of spirometric values.
Asthma control results
The proportions of patients with different levels of
asthma control in the two study groups and in the
whole study population are shown in Table 3 and on
Figure 1. Comparing the two device types, a significantly
higher proportion of controlled patients was observed in
the pMDI group when compared to DPI group (p =
0.031; Chi-square test)
Table 1 Questionnaire for the assessment of asthma control
1. Have daytime asthma symptoms occurred during the last week (dyspnoea, shortness of breath, wheezing)?
a. No 0 points
b. Yes, maximum twice a week 1 point
c. Yes, more than twice a week 5 points
2. Have night-time symptoms occurred OR have you been woken up by asthma symptoms during the last week?
a. No 0 points
b. Yes, but I am not sure if it was asthma 1 point
c. Yes 5 points
3. Have you felt any limitation during physical activity during the last week?
a. No 0 points
b. Yes, but only during hard physical work 1 point
c. Yes, during normal daily activities 5 points
4. How frequently have you used reliever therapy during the last week(Ventolin/Berotec/Berodual/Salbutamol/Atrovent/Bricanyl/
Symbicort reliever)?*
a. Never 0 points
b. Twice or less 1 point
c. More than twice 5 points
5. Have you had an acute exacerbation/attack of asthma that resulted in emergency department/hospitalization since you
started using this maintenance therapy?
a. No 0 points
b. Yes 5 points
Total score:
CONTROLLED ASTHMA = 0-4 points
PARTIALLY CONTROLLED ASTHMA = 5-14 points
UNCONTROLLED ASTHMA = more than 14
* Ventolin/Berotec/Berodual/Salbutamol/Atrovent were all MDI formulations.
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the extrafine pMDI group as compared to the DPI group
(p = 0.016) indicating a better asthma control in extrafine
pMDI-treated patients (Figure 2). When looking at single
domains of asthma control, mean daytime symptom
score was significantly lower in the extrafine pMDI group
as compared to the DPI group (p = 0.012), demonstrating
better symptom control in patients using extrafine pMDI
(Figure 2). The same was true for rescue medication use
that was significantly lower in the extrafine pMDI group
(p = 0.025; Figure 2). Scores representing night-time
symptoms and physical activity limitation did not differ
significantly between the two groups.
Notably, the mean daily ICS dose was significantly
lower in the extrafine pMDI group as compared to the
DPI group, suggesting an overall better asthma control
with a lower steroid load (p < 0.001; Figure 3).
Asthma control levels detected by the questionnaire
adopted in this study were in good agreement with the
control levels assessed by using the current GINA
guidelines. According to GINA-based control assess-
ment (that includes lung function values as well),
38.74% of the patients proved to be controlled, 38.74%
and 22.52% partially controlled and uncontrolled,
respectively.
Subgroup of smoking patients
Current or previous smoking was common in asthmatic
patients enrolled in this study (35%), with a mean smok-
ing history of 19.0 ± 3.6 pack/years. No gender differ-
ence between smokers was noted. While smoking status
did not influence steroid dose used, it significantly
increased the proportion of uncontrolled patients as
compared to never smokers (11% vs. 23%, p < 0.05).
Asthma control in smokers is summarized in Table 4.
Discussion
This is the first real-life study comparing the clinical
effects of BDP/F extrafine to other combinations. Pre-
viously published RCTs found that there were no differ-
ences between BDP/F extrafine pMDI and BUD/F or
FP/S in terms of lung function, use of rescue medica-
tions, exacerbations and safety [22,23]. However, these
studies do not reflect routine use, during which compli-
ance or each patient’s ability to use the device may
influence the result. In addition to the improved lung
deposition and distribution, there is less reliance on
using an optimal inhalation technique for pMDIs formu-
lated with extrafine particles [8]. Although these were
not assessed in this study, the result would include
these elements. Previous studies have shown that, when
Table 2 Clinical characteristics and lung function parameters in different treatment groups
BDP/F extrafine pMDI (n = 53) BUD/F and FP/S DPI (n = 58)
Male, n (%) 15 (28.3%) 15(25.8%)
Age, years (mean and range) 48 (19-84) 47 (18-86)
Current smokers, n (%) 20 (37.7%) 19 (32.8%)
Allergies, n (%) 40 (75.5%) 41 (70.6%)
Patients using SABA for as needed medication, n (%) 53 (100%) 50 (86.2%)
Patients using BUD/F for as needed medication, n (%) 0 (0%) 8 (13.8%)
Initial diagnosis of mild persistent asthma, n (%) 0 (0%) 0 (0%)
Initial diagnosis of moderate persistent asthma, n (%) 45 (84.9%) 49 (84.5%)
Initial diagnosis of severe persistent asthma, n (%) 8 (15.1%) 9 (15.5%)
FEV1(mean ± SE; % of predicted) 81.71 ± 17.53 79.38 ± 17.71
PEF (mean ± SE; % of predicted) 78.47 ± 19.92 75.34 ± 22.12
FEF 25-75 (mean ± SE; % of predicted) 62.35 ± 26.18 56.52 ± 23.3
MEF 75 (mean ± SE; % of predicted) 71.53 ± 28.38 71.41 ± 29.01
MEF 25 (mean ± SE; % of predicted) 58.2 ± 26.12 53.74 ± 24.23
SABA = short acting beta2-agonist; BDP = beclomethasone dipropionate; BUD = budesonide; FP = fluticasone propionate; F = formoterol; S = salmeterol.
#In
pMDI group spirometry data were not available in 2 patients.
Table 3 Proportion of patients with different levels of asthma control
BDP/F extrafine pMDI (n = 53) BUD/F and FP/S DPI (n = 58) All (n = 111)
Controlled 30 (56.60%)* 21 (36.21%) 51 (45.94%)
Partially controlled 17 (32.08%) 26 (44.83%) 43 (38.74%)
Uncontrolled 6 (11.32%) 11 (18.96%) 17 (15.32%)
BDP = beclomethasone dipropionate; BUD = budesonide; FP = fluticasone propionate; F = formoterol; S = salmeterol.* p = 0.031 vs. BUD/F and FP/S.
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Figure 1 Proportion of patients with different levels of asthma control in the two study groups; *p = 0.031 pMDI vs. BUD/F and FP/S.
BDP-beclomethasone dipropionate; BUD- budesonide; FP-fluticasone propionate; F-formoterol; S-salmeterol.
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Figure 2 Daytime symptom score, rescue medication use score and asthma control total score achieved by BDP/F extrafine pMDI or
BUD/F and FP/S DPI; *p = 0.012,
#p = 0.025, and
^p = 0.016, respectively (Mann-Whitney Test for BDP/F vs. BUD/F and FP/S). BDP-
beclomethasone dipropionate; BUD- budesonide; FP-fluticasone propionate; F-formoterol; S-salmeterol.
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Page 5 of 8inhalers emitting large particles are used, the magnitude
of inhalation technique errors for a pMDI and DPI are
similar [12].
The results show that asthma control was significantly
better in patients receiving BDP/F extrafine pMDI for-
mulation compared to the DPI group. Daytime symp-
toms and use of rescue medications were significantly
lower in the BDP/F extrafine pMDI group, further sup-
porting a greater control of asthma in a real-life setting.
Asthma is an inflammatory disorder affecting both cen-
tral and peripheral airways [24,25], which justifies the
clinical need for anti-asthmatic medication which is also
able to reach peripheral airways. The inverse correlation
on particle size and pulmonary deposition is well
known [26]. Of the fixed combinations of ICS currently
available on the market, BDP/F extrafine pMDI drug
particles are approximately half the size in diameter
compared to FP/S and BUD/F DPIs [17]. BDP/F extra-
fine pMDI is the only fixed combination which has
been demonstrated to reach not only large, but also
small airways when administered in asthmatic patients
[15]. Accordingly, the improved drug delivery, which
enables a more uniform treatment of inflammation and
bronchoconstriction throughout the entire bronchial
tree, contributes to the higher level of asthma control
achieved with BDP/F extrafine combination in this
study. In other words, extrafine BDP/F can reach and
treat distal areas of the lung left untargeted by larger
particle sized medications, and this translates into a
greater clinical benefit for patients. A significantly
superior asthma control with the BDP/F extrafine com-
bination vs. the combination of the same drugs (BDP
plus F) given as larger particles, non extrafine agents,
has been found in a large 6-month RCT carried-out in
asthmatic patients [16]. However, in this study, the defi-
nition of asthma control was established according to
Zetterström [27] and was therefore different from the
GINA guidelines, which is a limitation of our analysis.
No differences in lung function parameters were
observed among treatments. This finding is not surpris-
ing considering that the spirometric tests performed in
this study do not provide comprehensive evaluation of
the entire bronchial tree as they are unable to properly
reflect small airway abnormalities.
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Figure 3 Mean daily ICS doses (μg) in the different groups of patients. *p < 0.0001 BDP/F vs. BUD/F and FP/S. BDP-beclomethasone
dipropionate; BUD- budesonide; FP-fluticasone propionate; F-formoterol; S-salmeterol.
Table 4 Asthma control in smoker subgroups
BDP/F extrafine pMDI (n = 20) BUD/F and FP/S DPI (n = 19) All (n = 39)
Controlled 12 (60%) 8 (42.1%) 20 (51.3)
Partially controlled 5 (25%) 5 (26.3%) 10 (25.6%)
Uncontrolled 3 (15%) 6 (31.6%) 9 (23.1%)
BDP = beclomethasone dipropionate; BUD = budesonide; FP = fluticasone propionate; F = formoterol; S = salmeterol.
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not excluded since they represent a large proportion of
asthmatic patients. Generally, the level of asthma control
in smokers was similar to that in non smokers; however,
the proportion of uncontrolled patients was significantly
increased in these patients as compared to never smokers.
Smoking asthmatics are mostly excluded from clinical
trials, therefore only sparse data are available on asthma
control in current or former smoker asthmatic patients.
Notably, these results were obtained with a lower
mean daily ICS dose indicating that BDP/F extrafine
delivers a greater efficacy per μg of steroid when com-
p a r e dt oB U D / Fa n dF P / S .T h i si so fi n t e r e s tc o n s i d e r -
ing that reduced compliance in asthmatic patients is
often due to steroid phobia, an issue that can be
decreased by offering a medication with a low corticos-
teroid dose [28].
In the studied population, 45.9% of patients had con-
trolled asthma, 38.7% were partially controlled, and
15.3% were uncontrolled. These findings are in agree-
ment with recent observational trials focusing on asthma
control. A study performed across 10 different European
countries showed that asthma is suitably controlled in
45% of non-inhaled corticosteroid users and only in 15%
of patients using ICS [1]. Similarly, a web-based survey
to assess the prevalence of uncontrolled asthma in the
United States reported that symptoms were successfully
controlled in 45% of patients [29].
This real-life observational study shows that GINA-
based asthma control is achieved in a good proportion of
asthmatic patients treated with fixed combinations of ICS
and LABA. Patients treated with BDP/F extrafine pMDI
achieved a greater level of asthma control as compared to
patients treated with FP/S or BUD/F larger particle com-
binations, suggesting that differences in inhaler devices
and formulations can have an impact on important clini-
cal outcomes and should be therefore taken into consid-
eration when managing patients with asthma.
Conclusions
In asthmatic patients with comparable disease severity,
the use of extrafine BDP/F combination formulated in a
pMDI demonstrated better asthma control than using
DPI fixed dose combinations formulated with larger par-
ticles. This could be due to the improved lung deposi-
tion and distribution of the dose or less reliance on the
optimal inhalation technique or both.
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